Story Health

Urgent Warning Over 'Heightmaxxing' Trend Among Teenagers

Health
The brief

Experts are sounding the alarm over a dangerous trend known as 'heightmaxxing', where teenagers, predominantly boys, are reportedly taking erdafitinib, a drug originally developed for treating advanced bladder cancer, in hopes of increasing their height. This alarming practice has emerged as teenagers are influenced by online posts that suggest the medication could enhance their growth. Dr. Stephanie Widmer, an emergency medicine physician in New York City, has expressed serious concerns, stating, "It's extremely concerning that teenagers are experimenting with powerful cancer medications in an attempt to grow taller. These drugs were developed to treat serious medical conditions, not to enhance physical appearance, and taking them without a legitimate medical indication or physician supervision can have devastating consequences."

Erdafitinib, marketed under the brand name Balversa, is approved by the Food and Drug Administration (FDA) specifically for urothelial carcinoma, which accounts for about 90 percent of the 84,000 bladder cancer cases diagnosed annually in the United States. While the drug functions by inhibiting a growth-driving protein in tumors, some studies have indicated it might also accelerate bone growth in younger patients, leading to speculation about its potential to increase height. However, this claim is contested by other scientists, and the risks associated with the drug are significant, including vision damage, severe muscle and bone pain, and other serious side effects.S1

Reports indicate that teenagers have been able to acquire erdafitinib from online vendors, often overseas, despite it being a prescription medication. One teenager, identified only as Zak, shared his experience of purchasing the drug online for $300 a month. He claimed to have grown several inches during the period he took the medication but suffered from severe joint pain and frequent nosebleeds, ultimately fearing hospitalization due to the adverse effects. This personal account underscores the potential dangers of using such powerful drugs without medical oversight.S1S2

Medical professionals continue to urge parents to be vigilant and educate their children about the dangers of misusing prescription medications. The trend raises significant public health concerns as it highlights the lengths to which some teenagers will go to alter their physical appearance, often influenced by social media and peer pressure. With the potential for lifelong complications from such reckless behavior, the medical community is calling for increased awareness and preventive measures to protect young individuals from the harmful consequences of 'heightmaxxing.'S1

Timeline · newest first
11h Dailymail

Urgent warning over 'heightmaxxing' trend where teenagers take cancer drugs to grow taller

Experts are issuing an urgent warning over a 'heightmaxxing' trend where teenagers take cancer drugs in an effort to get taller.

11h Internewscast

Heightmaxxing Trend Sparks Warning as Teens Take Cancer Drugs

Internewscast Internewscast Doctors are issuing an urgent warning to parents after reports that teenagers… This Post: Heightmaxxing Trend Sparks Warning as Teens Take Cancer Drugs…

Urgent Warning Over 'Heightmaxxing' Trend Among Teenagers

2 outlets 2 reports
The brief

Experts are sounding the alarm over a dangerous trend known as 'heightmaxxing', where teenagers, predominantly boys, are reportedly taking erdafitinib, a drug originally developed for treating advanced bladder cancer, in hopes of increasing their height. This alarming practice has emerged as teenagers are influenced by online posts that suggest the medication could enhance their growth. Dr. Stephanie Widmer, an emergency medicine physician in New York City, has expressed serious concerns, stating, "It's extremely concerning that teenagers are experimenting with powerful cancer medications in an attempt to grow taller. These drugs were developed to treat serious medical conditions, not to enhance physical appearance, and taking them without a legitimate medical indication or physician supervision can have devastating consequences."

Erdafitinib, marketed under the brand name Balversa, is approved by the Food and Drug Administration (FDA) specifically for urothelial carcinoma, which accounts for about 90 percent of the 84,000 bladder cancer cases diagnosed annually in the United States. While the drug functions by inhibiting a growth-driving protein in tumors, some studies have indicated it might also accelerate bone growth in younger patients, leading to speculation about its potential to increase height. However, this claim is contested by other scientists, and the risks associated with the drug are significant, including vision damage, severe muscle and bone pain, and other serious side effects.S1

Reports indicate that teenagers have been able to acquire erdafitinib from online vendors, often overseas, despite it being a prescription medication. One teenager, identified only as Zak, shared his experience of purchasing the drug online for $300 a month. He claimed to have grown several inches during the period he took the medication but suffered from severe joint pain and frequent nosebleeds, ultimately fearing hospitalization due to the adverse effects. This personal account underscores the potential dangers of using such powerful drugs without medical oversight.S1S2

Medical professionals continue to urge parents to be vigilant and educate their children about the dangers of misusing prescription medications. The trend raises significant public health concerns as it highlights the lengths to which some teenagers will go to alter their physical appearance, often influenced by social media and peer pressure. With the potential for lifelong complications from such reckless behavior, the medical community is calling for increased awareness and preventive measures to protect young individuals from the harmful consequences of 'heightmaxxing.'S1

Timeline · newest first

Sources · 2 citations

S1 Dailymail 1 report · EN
S2 InternewscastLead 1 report · EN